Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 3/20 | 0.54 |
| ▸ | RPS6KB1 | P23443 | 3/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | SYK | P43405 | 2/20 | 0.52 |
| ▸ | LDHB | P07195 | 9/20 | 0.50 |
| ▸ | LDHA | P00338 | 8/20 | 0.47 |
| ▸ | PLK1 | P53350 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | ASPH | Q12797 | 1/20 | 0.44 |
| ▸ | RIOX2 | Q8IUF8 | 1/20 | 0.44 |
| ▸ | KDM8 | Q8N371 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | PPP1CA | P62136 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22261197 | 0.88 | SYK (0.53) | AURKARPS6KB1AURKBSYKLDHB | |
| SCHEMBL22261344 | 0.86 | RPS6KB1 (0.51) | AURKARPS6KB1AURKBSYKLDHB | |
| SCHEMBL22261333 | 0.84 | SYK (0.55) | AURKARPS6KB1SYK | |
| SCHEMBL22261410 | 0.84 | AURKA (0.46) | AURKARPS6KB1AURKBSYKLDHB | |
| SCHEMBL22261133 | 0.83 | SYK (0.52) | AURKARPS6KB1SYK | |
| SCHEMBL22261260 | 0.83 | AURKA (0.45) | AURKARPS6KB1AURKBSYKEGFR | |
| SCHEMBL29922290 | 0.82 | RPS6KB1 (0.56) | AURKARPS6KB1AURKBEGFR | |
| SCHEMBL17485379 | 0.82 | MAPK8 (0.54) | SYK | |
| SCHEMBL22261309 | 0.82 | SYK (0.45) | AURKARPS6KB1AURKBSYK | |
| SCHEMBL30430694 | 0.82 | ALDH1A1 (0.64) | SYKLDHBLDHAKDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8853230-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-20130137673-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367689-B2 | Inhibitors of JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| US-20110005947-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2011-01-13 | — | — | US | disclosed |
| WO-2010129802-A1 | INHIBITORS OF JAK | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137673-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | AURKA 365/4885RPS6KB1 483/4885AURKB 405/4885 |
| US-20110005947-A1 | INHIBITORS OF JAK | JAK1, JAK2, JAK3 | AURKA 365/4885RPS6KB1 483/4885AURKB 405/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.